Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib-Reference-Cited by-同舟云学术

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

Published:2018-07-27 Issue:12 Volume:58 Page:1618-1628
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Morcos Peter N.¹,Cleary Yumi²,Sturm-Pellanda Carolina³,Guerini Elena²,Abt Markus³,Donzelli Massimiliano²,Vazvaei Faye¹,Balas Bogdana³,Parrott Neil²,Yu Li¹

Affiliation:

1. Roche Innovation Center; New York City NY USA

2. Roche Innovation Center; Basel Switzerland

3. F. Hoffmann-La Roche Ltd; Basel Switzerland

Funder

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.1286/fullpdf

Reference44 articles.

1. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases;Kodama;Cancer Chemother Pharmacol,2014

2. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance;Kodama;Cancer Lett,2014

3. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study;Ou;J Clin Oncol,2016

4. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial;Shaw;Lancet Oncol,2016

5. Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer;Gadgeel;J Clin Oncol,2016

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insuffisance d’organe (cœur, rein, foie) et traitements du cancer pulmonaire;Revue des Maladies Respiratoires Actualités;2023-10

2. Development and Validation of an Ecofriendly, Rapid, Simple and Sensitive UPLC-MS/MS Method for Entrectinib Quantification in Plasma for Therapeutic Drug Monitoring;Separations;2023-09-11

3. Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs;Cancer Chemotherapy and Pharmacology;2023-07-19

4. Brigatinib pharmacokinetics in patients with chronic hepatic impairment;Investigational New Drugs;2023-04-13

5. Design and conduct considerations for studies in patients with hepatic impairment;Clinical and Translational Science;2022-10-09